Complete response obtained by bortezomib plus dexamethasone in a patient with relapsed multiple myeloma with multiple plasmacytomas

A case of relapsed multiple myeloma (MM) with multiple plasmacytomas of the parietal bone and the right orbit in which was achieved a complete response with bortezomib plus dexamethasone (BD) therapy is reported. A Japanese woman with Bench-Jones lambda-type MM who achieved a plateau phase with nine...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2010-09, Vol.30 (9), p.3791-3794
Main Authors: Fukushima, Toshihiro, Nakamura, Takuji, Miki, Miyuki, Sakai, Tomoyuki, Iwao, Haruka, Nakajima, Akio, Sawaki, Toshioki, Fujita, Yoshimasa, Tanaka, Masao, Masaki, Yasufumi, Hirose, Yuko, Umehara, Hisanori
Format: Article
Language:English
Subjects:
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Boronic Acids - administration & dosage
Boronic Acids - adverse effects
Bortezomib
Dexamethasone - administration & dosage
Dexamethasone - adverse effects
Female
Humans
Multiple Myeloma - drug therapy
Multiple Myeloma - pathology
Multiple Myeloma - physiopathology
Neoplasm Recurrence, Local - drug therapy
Plasmacytoma - drug therapy
Plasmacytoma - pathology
Pyrazines - administration & dosage
Pyrazines - adverse effects
Tomography, X-Ray Computed
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A case of relapsed multiple myeloma (MM) with multiple plasmacytomas of the parietal bone and the right orbit in which was achieved a complete response with bortezomib plus dexamethasone (BD) therapy is reported. A Japanese woman with Bench-Jones lambda-type MM who achieved a plateau phase with nine courses of melphalan plus prednisolone therapy complained of right exophthalmos and numbness around her mouth. Computed tomographic (CT) scan and T2-weighted magnetic resonance imaging showed tumours at the parietal bone and the right orbit. A tumour biopsy from the parietal bone revealed the histological morphology of a plasmacytoma. She was therefore diagnosed with relapsed MM with multiple plasmacytomas, and received BD therapy. A CT scan after the end of the second course of treatment revealed the disappearance of the plasmacytomas. At the end of the fifth course, no lambda light chain was detected by immunofixation of serum and urine, and the pathological plasma cells in bone marrow were fewer than 5%; therefore, she had achieved a complete response. The time to disease progression from the first course of BD therapy and the treatment-free interval were 400 days and 134 days, respectively. This case report indicates that bortezomib may be a promising agent for MM with multiple plasmacytomas.
ISSN:1791-7530